Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-8)

Sum=58

Aug 26, 2025 (publication date) through Aug 21, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Evidence Review

World J Cardiol. Aug 26, 2025; 17(8): 107991
Published online Aug 26, 2025. doi: 10.4330/wjc.v17.i8.107991

Full Size Figure Download Figure

Figure 8 Stages of development of various incretin agonists. GLP-1: Glucagon-like peptide-1; LAR: Long-acting release.

Citation: Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World J Cardiol 2025; 17(8): 107991
URL: https://www.wjgnet.com/1949-8462/full/v17/i8/107991.htm
DOI: https://dx.doi.org/10.4330/wjc.v17.i8.107991